GlassScriptPhysician profile
Tara Iyengar
NPI 1922217660
$11,456.20
in general payments reported to CMS, 2019-2025
71 companies · $2,684 in 2025
The $2,684 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $510 · 2021: $1,584 · 2022: $2,164 · 2023: $1,398 · 2024: $2,247 · 2025: $2,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,163 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,162.76 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,420.25 | 2019-2025 | |
| Pfizer INC. | $791.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $647.14 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $575.47 | 2019-2025 | Enhertu, Imfinzi |
| Genentech USA, INC. | $539.30 | 2019-2025 | Alecensa, Polivy, Tecentriq |
| Janssen Biotech, INC. | $478.42 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $440.39 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $430.77 | 2019-2025 | Opdivo, Opdualag |
| Amgen INC. | $396.54 | 2019-2023 | Xgeva, Nplate, Vectibix |
| Genzyme Corporation | $377.09 | 2019-2025 | |
| Lilly USA, LLC | $301.77 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Incyte Corporation | $262.47 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $241.63 | 2019-2025 | Fruzaqla, Iclusig, Alunbrig |
| Daiichi Sankyo INC. | $241.52 | 2020-2025 | Enhertu, Injectafer, Vanflyta |
| Stemline Therapeutics INC. | $233.27 | 2024-2025 | Orserdu |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Iyengar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.